

Medicare Part B Preferred drug list — Aetna Better Health® Premier Plan (Medicare-Medicaid Plan).

Some medically administered Part B drugs may have extra requirements or limits on coverage. These may include step therapy. This is when we require you to first try certain preferred drugs to treat your medical condition before covering another non-preferred drug.

For example, if drug A and drug B both treat your condition, we may prefer drug A, and require you to try it first. If drug A does not work for you, we will then cover drug B. The listed preferred products should be used first. An exception process is in place for specific cases that may call for a non-preferred product.

Drug classes with preferred products are listed below. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna® website.

To find out more, go to AetnaBetterHealth.com/Michigan.

You can also call us at the number on your ID card.

Drug Class/Indication(s)	Non-Preferred Product(s)	Preferred Product(s)
Alpha-1 proteinase inhibitors	Aralast NP Glassia	Prolastin-C Zemaira
Bone Resorption Inhibitors* • Osteoporosis *Both preferred products required prior to receiving non-preferred product	Evenity	Prolia AND Zoledronic acid
 Bone Resorption Inhibitors Hypercalcemia of malignancy Prevention of skeletal events in multiple myeloma Prevention of skeletal events in prostate cancer or solid tumors with bone metastases Treatment of osteopenia or osteoporosis in systemic mastocytosis 	Xgeva	Pamidronate Zoledronic acid
 Botulinum Toxins Blepharospasm Cervical dystonia Chronic sialorrhea Upper limb spasticity 	Daxxify Dysport Myobloc	Botox Xeomin





		January 2025
Botulinum ToxinsAll other indications		Botox
Complement Inhibitors Hemolytic uremic syndrome Paroxysmal nocturnal hemoglobinuria		Soliris Ultomiris
Complement Inhibitors • Neuromyelitis optica spectrum disorder		Soliris
Myasthenia gravis	Rystiggo	Soliris <u>Ultomiris</u> <u>Vyvgart</u> <u>Vyvgart Hytrulo</u>
Colony Stimulating Factors (short-acting)	Granix Leukine Neupogen Nivestym Releuko	Zarxio
Colony Stimulating Factors (long-acting)	Fylnetra Nyvepria Rolvedon Ryzneuta Stimufend Udenyca Ziextenzo	Fulphila Neulasta Neulasta Onpro
 Erythropoiesis Stimulating Agents Anemia due to chronic kidney disease Anemia due to chemotherapy 	Epogen Retacrit Jesduvroq	Aranesp Procrit
 Erythropoiesis Stimulating Agents Anemia due to Zidovudine use in HIV Transfusion reduction for select surgeries 	Vafseo	Procrit
Enzyme replacement therapy	Vpriv	Cerezyme Elelyso
Factor VIII (recombinant) • Hemophilia A (prophylaxis)	Advate Afstyla Nuwiq NovoEight Xyntha	Kovaltry
Geographic atrophy	Izervay	Syfovre





		January 2025
Gonadotropin-Releasing Hormone Agonists • Advanced prostate cancer	Lupron depot Trelstar Zoladex	Eligard
Gonadotropin-Releasing Hormone Antagonists		Firmagon
Immunologics (B through B) • Ulcerative colitis	Avsola Omvoh Remicade Unbranded infliximab	Entyvio Inflectra Renflexis
Immunologics (B through B) • Crohn's disease		Entyvio
 Intravenous iron Iron deficiency anemia after intolerance or unsatisfactory response to oral iron 	Feraheme Injectafer Monoferric	Ferrlecit Sodium ferric gluconate Infed Venofer
IVIG (intravenous immunoglobulin)	Asceniv Bivigam Flebogamma Gammagard Liquid Gammagard S/D Gammaplex Panzyga	Gammaked Gamunex-C Octagam Privigen
SCIG (subcutaneous immunoglobulin)	Cutaquig Cuvitru Gammagard Liquid HyQvia	Gammaked Gamunex-C Hizentra Xembify
Multiple Sclerosis	Briumvi Lemtrada	Ocrevus
Oncology • Breast cancer	Perjeta	Tysabri Phesgo
Oncology (Abraxane)	Abraxane Paclitaxel (protein bound)	Docetaxel Paclitaxel
Oncology (Avastin)	Alymsys Avastin Avzivi Vegzelma	Mvasi Zirabev





		January 2025
Oncology (Herceptin)	Herceptin Herceptin Hylecta Herzuma Ogivri Ontruzant	Kanjinti Trazimera
Oncology (Multiple myeloma)	Darzalex Darzalex Faspro Empliciti Kyprolis Sarclisa	Bortezomib
Oncology (PD1/PDL1) • Squamous cell carcinoma	Keytruda	Libtayo
Oncology (PD1/PDL1) • Non-small cell lung cancer	Imfinzi Keytruda Opdivo Tecentriq	Libtayo
Oncology (Pemetrexed)	Pemfexy	Alimta Pemetrexed
Oncology (Rituximab) • All requests except rheumatoid arthritis	Riabni Rituxan Rituxan Hycela	Ruxience Truxima
Osteoarthritis	Zilretta	Kenalog Depo-medrol Triamcinolone acetonide Methylprednisolone acetate
Severe asthma	Cinqair Nucala Tezspire Xolair	Fasenra
Somatostatin analogues	Lanreotide (Cipla) Sandostatin LAR Signifor LAR	Somatuline depot





		January 2025
VEGF inhibitors (ophthalmic)	Beovu Cimerli Lucentis Susvimo Vabysmo	Bevacizumab (Avastin) Byooviz or Eylea/Eylea HD after trial/failure of bevacizumab (Avastin)
Viscosupplements (single injection)	Gel-One Monovisc	Durolane Synvisc-One
Viscosupplements (multiple injections)	Gelsyn-3 GenVisc Hyalgan Hymovis Orthovisc Supartz FX TriVisc Visco-3	Euflexxa Synvisc

For the following classes, preferred products may be covered under the Part D (pharmacy) benefit:

Drug Class	Non-preferred Product(s)	Preferred Product(s)
Immunologics • Crohn's disease	Actemra Avsola Cimzia Ilumya Inflectra Orencia	Humira Idacio Rinvoq Skyrizi Stelara
Immunologics • Ankylosing spondylitis	Remicade Renflexis Riabni Rituxan Ruxience Simponi Aria	Cosentyx Enbrel Humira Idacio Rinvoq Xeljanz/Xeljanz XR
Immunologics • Juvenile idiopathic arthritis	Truxima Tyruko Tysabri Unbranded infliximab	Enbrel Humira Idacio Tyenne Xeljanz/Xeljanz XR





		January 2023
Immunologics • Plaque psoriasis		Cosentyx Enbrel Humira Idacio Skyrizi Sotyktu Stelara Tremfya
Immunologics • Psoriatic arthritis		Cosentyx Enbrel Humira Idacio Rinvoq Skyrizi Stelara Tremfya Xeljanz/Xeljanz XR
Immunologics • Rheumatoid arthritis		Enbrel Humira Idacio Rinvoq Tyenne Xeljanz/Xeljanz XR
PCSK9 inhibitors	Leqvio	Repatha
Systemic lupus erythematosus	Saphnelo	IV Benlysta (Part B) SC Benylsta (Part D)

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna website.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Aetna. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed Proprietary MI-23-08-37 H8026_24PTBPDL APPROVED





therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

See Member Handbook for a complete description of plan benefits, exclusions, limitations, and conditions of coverage. Plan features and availability may vary by service area. The formulary and/or pharmacy network may change at any time. You will receive notice when necessary.

Aetna Better Health Premier Plan is a health plan that contracts with both Medicare and Michigan Medicaid to provide benefits of both programs to enrollees.

©2023 Aetna Inc.